The HCP5 Polyclonal Antibody (PAC047958) is a valuable tool for researchers studying HCP5, a long non-coding RNA that has been implicated in various biological processes, including immune regulation and cancer development. This antibody, produced in rabbits, exhibits high reactivity with human samples and has been validated for use in Western blot applications. By binding to the HCP5 molecule, this antibody enables researchers to detect and analyze its expression in different cell types, making it an ideal choice for studies in immunology and oncology.
HCP5, also known as MEG3-2, has been reported to play a role in immune response modulation, making it a potential target for therapeutic interventions in diseases such as cancer and autoimmune disorders. Understanding the function of HCP5 is essential for unraveling its involvement in these pathologies and for the development of novel treatment strategies. Researchers can rely on the HCP5 Polyclonal Antibody to provide reliable and reproducible results in their investigations into the role of HCP5 in health and disease.
Antibody Name:
HCP5 Antibody (PACO47958)
Antibody SKU:
PACO47958
Size:
50ug
Host Species:
Rabbit
Tested Applications:
ELISA, IHC
Recommended Dilutions:
ELISA:1:2000-1:10000, IHC:1:20-1:200
Species Reactivity:
Human
Immunogen:
Recombinant Human HLA class I histocompatibility antigen protein P5 protein (8-101AA)
Immunohistochemistry of paraffin-embedded human spleen tissue using PACO47958 at dilution of 1:100.
Immunohistochemistry of paraffin-embedded human lymph node tissue using PACO47958 at dilution of 1:100.
Background:
defense response
Synonyms:
HLA class I histocompatibility antigen protein P5 (HLA complex protein P5) (Protein P5-1), HCP5
UniProt Protein Function:
MiscellaneousVariation Gly-112 is associated with low viral loads in untreated HIV patients. The level of circulating virus in the plasma of HIV patients (viral set point) varies among individuals during the nonsymptomatic phase preceding the progression to AIDS. This polymorphism explains 9.6% of the total variation in set point and is associated with the HLA-B*5701 allele, which has the strongest described protective impact on HIV disease progression. However, it is possible that HPC5 polymorphism, and not HLA-B*5701 allele, plays a direct role in the control in viremia in HIV patients.
